• / Free eNewsletters & Magazine
  • / My Account
Home>ALung Receives IDE Approval to Conduct VENT-AVOID Trial of the Hemolung RAS for the US Market

ALung Receives IDE Approval to Conduct VENT-AVOID Trial of the Hemolung RAS for the US Market

ALung Receives IDE Approval to Conduct VENT-AVOID Trial of the Hemolung RAS for the US Market

09/27/2017

ALung Receives IDE Approval to Conduct VENT-AVOID Trial of the Hemolung RAS for the US Market

ALung Technologies, Inc., today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) to conduct a pivotal clinical trial of the Hemolung® Respiratory Assist System for the treatment of adults with severe acute exacerbation of chronic obstructive pulmonary disease (COPD). The FDA’s approval of the IDE makes ALung’s VENT-AVOID Trial the first pivotal trial of extracorporeal carbon dioxide removal (ECCO2R) for treating patients with COPD exacerbations.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170927006053/en/

The Hemolung RAS is an investigational device from ALung Technologies which provides extracorporeal ...

The Hemolung RAS is an investigational device from ALung Technologies which provides extracorporeal carbon dioxide removal for patients with acute respiratory failure due to acute exacerbation of COPD. (Photo: Business Wire)

“The achievement of FDA approval for initiation of the VENT-AVOID Trial is an important milestone towards making the Hemolung RAS and ECCO2R therapy available to US patients and their physicians,” said Peter DeComo, Chairman and CEO of ALung. “We believe that there is great potential for the Hemolung technology to facilitate ventilator avoidance, resulting in improved clinical outcomes and a lower cost of care through a reduction in length of stay in the intensive care unit.”

The VENT-AVOID Trial is a prospective, multi-center, randomized, controlled, pivotal trial to validate the safety and efficacy of the Hemolung Respiratory Assist System for COPD patients experiencing an acute exacerbation requiring ventilatory support. Forty hospitals will enroll up to 800 patients in the trial. The study protocol is built around a state of the art adaptive statistical plan which will allow for PMA submission when early success criteria are reached, potentially with as few as 300 patients enrolled. COPD patients suffering severe exacerbations will be eligible for the study if they are either 1) failing non-invasive ventilation and presenting a high risk of being intubated and mechanically ventilated or 2) have required intubation and invasive mechanical ventilation due to acute respiratory failure. Serving as the study principal investigator is Dr. Nicholas Hill, MD, Chief, Division of Pulmonary, Critical Care and Sleep Medicine at Tufts Medical Center. Dr. Hill is an international leader in pulmonary critical care medicine, having led studies which established non-invasive ventilation as the standard of care for COPD exacerbations.

In addition to the US-based VENT-AVOID study, The Hemolung RAS is also being studied in a landmark pivotal study for patients with acute respiratory distress syndrome (ARDS) as part of the 1,120-patient REST Trial in the United Kingdom. “Our commitment to clinical science runs very deep,” added Mr. DeComo. “We will soon be the only company participating in not just one, but two major pivotal trials validating the safety and efficacy of extracorporeal carbon dioxide removal therapy provided by the Hemolung RAS.”

ALung worked collaboratively with the FDA under its Expedited Access Pathway (EAP) program to obtain IDE approval. The Expedited Access Pathway is a new FDA program aimed to facilitate more rapid patient access to breakthrough technologies intended to treat or diagnose life-threatening or irreversibly debilitating diseases or conditions. ALung will continue to collaborate with the FDA during study enrollment and through the PMA process.

©2017 Morningstar Advisor. All right reserved.